116 related articles for article (PubMed ID: 11423937)
21. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.
Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI
Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
23. Effective high-dose chemotherapy combined with CD34+-selected autologous peripheral blood stem cell transplantation in a patient with cutaneous CD30-negative large T cell lymphoma.
Nishio M; Koizumi K; Endo T; Takashima H; Haseyama Y; Fujimoto K; Yamamoto S; Kobayashi H; Koike T; Sawada K
Bone Marrow Transplant; 2000 Jun; 25(12):1315-7. PubMed ID: 10871740
[TBL] [Abstract][Full Text] [Related]
24. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
25. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
[TBL] [Abstract][Full Text] [Related]
26. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
27. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
28. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Peinert S; Prince HM; Guru PM; Kershaw MH; Smyth MJ; Trapani JA; Gambell P; Harrison S; Scott AM; Smyth FE; Darcy PK; Tainton K; Neeson P; Ritchie DS; Hönemann D
Gene Ther; 2010 May; 17(5):678-86. PubMed ID: 20200563
[TBL] [Abstract][Full Text] [Related]
29. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
[TBL] [Abstract][Full Text] [Related]
30. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
[TBL] [Abstract][Full Text] [Related]
31. Recombinant Sendai virus vectors for activated T lymphocytes.
Okano S; Yonemitsu Y; Nagata S; Sata S; Onimaru M; Nakagawa K; Tomita Y; Kishihara K; Hashimoto S; Nakashima Y; Sugimachi K; Hasegawa M; Sueishi K
Gene Ther; 2003 Aug; 10(16):1381-91. PubMed ID: 12883535
[TBL] [Abstract][Full Text] [Related]
32. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
33. [Cutaneous lymphoma of the Sézary and Bouvrain type. Progress in physiopathologic and therapeutic outlook].
Bagot M
Bull Acad Natl Med; 1998; 182(5):927-37; discussion 937-8. PubMed ID: 9735499
[TBL] [Abstract][Full Text] [Related]
34. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
35. Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.
Baker C; Chang L; Elsegood KA; Bishop AJ; Gannon DH; Narendran P; Leech NJ; Dayan CM
Clin Exp Immunol; 2007 Mar; 147(3):472-82. PubMed ID: 17302896
[TBL] [Abstract][Full Text] [Related]
36. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells.
Lin SJ; Cheng PJ; Hsiao SS
Bone Marrow Transplant; 2006 May; 37(9):881-7. PubMed ID: 16565741
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.
Somasundaram R; Jacob L; Swoboda R; Caputo L; Song H; Basak S; Monos D; Peritt D; Marincola F; Cai D; Birebent B; Bloome E; Kim J; Berencsi K; Mastrangelo M; Herlyn D
Cancer Res; 2002 Sep; 62(18):5267-72. PubMed ID: 12234995
[TBL] [Abstract][Full Text] [Related]
38. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.
Hombach A; Schneider C; Sent D; Koch D; Willemsen RA; Diehl V; Kruis W; Bolhuis RL; Pohl C; Abken H
Int J Cancer; 2000 Oct; 88(1):115-20. PubMed ID: 10962448
[TBL] [Abstract][Full Text] [Related]
39. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
40. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
